Clinical trials: completed, sponsored by Bayer
Hypertension, Essential
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed
Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the corresponding loose combination under fed…
- Trial name
- NCT01350609
- Testing
- Nifedipine/Candesartan (BAY 98-7106), Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bayer
Hemophilia A
Colorado Adult Joint Assessment Scale (CAJAS) Validation
To obtain evidence of content validity and reliability of the Colorado Adult Joint Assessment Scale (CAJAS), a clinician-reported outcome (ClinRO) measure, as adapted for use in a population of adults with moderate to severe…
- Trial name
- CAJAS (NCT02284789)
- Testing
- Colorado Adult Joint Assessment Evaluation
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Endometriosis
Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients
This study is aimed to evaluate efficacy and safety of dienogest 2 mg oral tablets in the treatment of endometriosis. There will be 2 study phases: a double-blind, randomized, placebo-controlled, parallel-group phase over 24…
- Trial name
- NCT01822080
- Testing
- Dienogest (Visanne, BAY86-5258)
- Where
- 26 sites in China
- Volunteers
- 250 people
- Sponsor
- Bayer
Neoplasm
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Continuous dosing of BAY73-4506 in patients with advanced cancer
- Trial name
- NCT01117623
- Testing
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Bayer
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Magnetic Resonance Imaging
Contrast-enhanced MRI in Children 2 Months to <2 Years
The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age
- Trial name
- NCT00937391
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Where
- 13 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Bayer
Erectile Dysfunction, Metabolic Syndrome
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
This is a controlled, randomized, multi-center prospective study of vardenafil to determine efficacy on Erectile Dysfunction (ED), tolerability and safety in men with ED and Metabolic Syndrome.
- Trial name
- NCT00738400
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- 19 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Bayer
Contraception
Yasmin Post Marketing Surveillance
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.
- Trial name
- NCT00923572
- Testing
- EE30/DRSP (Yasmin, BAY86-5131)
- Where
- South Korea
- Volunteers
- 777 people
- Sponsor
- Bayer
Atrial Fibrillation (Prevention of Stroke)
Real-Life Evidence on Stroke Prevention in SPAF
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
- Trial name
- RELIEF (NCT02485873)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists
- Where
- Germany
- Volunteers
- 8,607 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety…
- Trial name
- SORINT (NCT01908322)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Multiple Sclerosis
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.
- Trial name
- NCT00370071
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Bayer
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Neoplasms
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
This Phase 1 study will be conducted in an open-label, non-randomized, dose-escalation design in subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy.
- Trial name
- NCT01585870
- Testing
- Sorafenib (Nexavar, BAY43-9006), Eribulin
- Where
- 4 sites in France, Germany
- Volunteers
- 40 people
- Sponsor
- Bayer
Hypertension, Pulmonary
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID.
- Trial name
- NCT00454558
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 15 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis (RRMS)
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS).
- Trial name
- BEACON (NCT00787657)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 36 sites in Argentina, Bahrain and 34 more
- Volunteers
- 1,723 people
- Sponsor
- Bayer
Contraception
Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction
This is local prospective, non-interventional multi-center comparative study. Primary study objective is evaluation of the user satisfaction with Mirena or Copper IUD up to 1 year after insertion ( patient assessment…
- Trial name
- Mirabel (NCT01590537)
- Testing
- Levonorgestrel (Mirena, BAY86-5028), Copper IUD
- Where
- Russia
- Volunteers
- 2,348 people
- Sponsor
- Bayer
Contraception
Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion
To observe the bleeding patterns of post-abortion immediate insertion of IUS compared to Cu-IUD over the first 6 months.
- Trial name
- POST (NCT01958684)
- Testing
- Levonorgestrel IUS (Mirena, BAY86-5028), Copper-IUD
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Bayer
Contraceptives, Oral
Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction
Prospective, non-interventional, multi-center study. Each subject will be followed for up to twelve months during the treatment with oral hormonal contraceptives(Qlaira ® or a Progestin Only Pill).
- Trial name
- NCT01200186
- Testing
- EV/DNG (Qlaira, BAY86-5027), Progestin Only Pills
- Where
- 11 sites in Czechia, France and 9 more
- Volunteers
- 3,258 people
- Sponsor
- Bayer
Chagas Disease
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
This study will evaluate the bioequivalence as well as safety and tolerability of a novel 30 mg tablet of nifurtimox compared to the corresponding marketed 120 mg tablet in adult subjects suffering from chronic Chagas' disease…
- Trial name
- NCT01927224
- Testing
- Nifurtimox (BAYa2502) (4 x 30 mg tablet), Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water), Nifurtimox (BAYa2502) (120 mg tablet)
- Where
- Argentina
- Volunteers
- 37 people
- Sponsor
- Bayer
Pain
Actual Use Trial of Naproxen Sodium
An actual use trial to demonstrate that consumers will not exceed the labeled daily dose of Aleve 24 Hour at an unacceptable rate.
- Trial name
- Kiefer AUT (NCT01427803)
- Testing
- Naproxen Sodium ER (BAYH6689)
- Where
- 34 sites in United States
- Volunteers
- 778 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.